Streptonigrin

Overview

Streptonigrin (Bruneomycin) is an orally active antibiotic and pan-PAD inhibitor, inhibiting PAD1 , PAD2 , PAD3 and PAD4 with IC 50 of 48.3 μM, 26.1 μM, 0.43 μM and 2.5 μM, respectively. Streptonigrin inhibits SENP1 ( IC 50 of 0.518 μM) and reduces HIF1α . Streptonigrin increases p53 and Apoptosis . Streptonigrin shows antiviral activity against Rauscher murine leukemia virus. Streptonigrin has immunosuppressive effects. Streptonigrin has antitumor activity against osteosarcoma.

Application

Products | Products > Disease Areas > Infection | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > Anti-infection | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Infection | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > MDM-2/p53 | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Antibiotic | Products > Signaling Pathways > Protein Arginine Deiminase | Products > Signaling Pathways > E1/E2/E3 Enzyme | Products > Signaling Pathways > HIF/HIF Prolyl-Hydroxylase

Product Information

• Catalog No.: HY-124586
• CAS No.: 3930-19-6
• Molecular Formula: C25H22N4O8
• Molecular Weight: 506.46
• Purity: 99.9%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source